Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about RFL, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Corticosteroid | ASTHMA | Phase 4 · NCT01089322 | Completed |
| Ascorbic Acid | Colonoscopy Preparation | Phase 4 · NCT02073552 | Completed |
| Polyethylene Glycol 4000 | Colonoscopy Preparation | Phase 4 · NCT02073552 | Completed |
| Biperiden | Brain Injury Traumatic Moderate | Phase 3 · NCT04945213 | Recruiting |
| Brazilian Green Propolis Extract (EPP-AF) | Covid19 | Phase 2/3 · NCT04480593 | Completed |
| Autologous mesenchymal cells transplantation | Spinal Cord Injury | Phase 2 · NCT02574585 | Unknown |
| Autologous thyTreg | Heart Transplantation | Phase 1/2 · NCT04924491 | Recruiting |
| Infusion of bone marrow mononuclear cells. | Chronic Hepatitis | Phase 2 · NCT02171949 | Unknown |
| intravenous treatment with EVs | Severe Acute Respiratory Syndrome (SARS) | Phase 1/2 · NCT06002841 | Unknown |
| Plasma rich in growth factors (PRGF-Endoret) | Infertility | Phase 2 · NCT03387501 | Completed |
| Propolis Period (Green Propolis 250mg/day) | Chronic Kidney Disease Requiring Chronic Dialysis | Phase 1/2 · NCT04072341 | Completed |
| Multiple doses of anti-SARS-CoV-2 Convalescent… | COVID-19 | Early Phase 1 · NCT05595538 | Completed |
Also used in these trials (approved or third-party drugs, not RFL's own candidates): Nicotine, Varenicline, Filgrastim.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
RFL holds $22.1M in cash and short-term investments (as of Jul 31, 2026) and burns about $7.8M/quarter from operations, an estimated runway of 8.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
As a result, management has concluded that substantial doubt exists regarding our ability to continue as a going concern.10-K, Oct 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RFL files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Howard S Jonas Exec Chairman, CEO & President, Director |
Insider | 15,042,008 | 15,042,008.00% | 2026-07-29 |
| Rafael Holdings, Inc. 10% owner |
Insider | 12,998,194 | 12,998,194.00% | 2024-12-23 |
| I9 Plus, LLC | 5%+ holder (13D) | 3,616,431 | 3,616,431.00% | 2025-06-05 |
| William Conkling Chief Executive Officer · +7,847 options |
Insider | 564,455 | 564,455.00% | 2025-03-25 |
| N Scott Fine Director |
Insider | 335,348 | 335,348.00% | 2025-07-14 |
| David Polinsky Chief Financial Officer |
Insider | 292,839 | 292,839.00% | 2026-10-25 |
| Markus Sieger Director |
Insider | 219,710 | 219,710.00% | 2026-01-28 |
| Michael J Weiss Director |
Insider | 141,861 | 141,861.00% | 2026-01-28 |
| Stephen M Greenberg Director |
Insider | 102,491 | 102,491.00% | 2025-01-06 |
| Mark N Stein Director |
Insider | 50,845 | 50,845.00% | 2026-01-28 |
| John Goldberg CHIEF MEDICAL OFFICER |
Insider | 50,000 | 50,000.00% | 2025-01-13 |
| Joshua M Fine Chief Operating Officer · +24,558 options |
Insider | 9,380 | 9,380.00% | 2025-09-03 |
Share count 100 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RFL and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →